Key result
Transapical LV lead implantation shows ~47% survival but is linked to major ischemic cerebrovascular events.
Why the study?
Does transapical left ventricular endocardial lead implantation cause long-term cerebral thromboembolic complications in heart failure patients with a failed transvenous approach?
Observational (n=26)
No
Does transapical left ventricular endocardial lead implantation cause long-term cerebral thromboembolic complications in heart failure patients with a failed transvenous approach?
Transapical left ventricular endocardial lead implantation has a comparable long-term mortality rate to conventional CRT but carries a worrisome risk of major ischemic cerebrovascular events, questioning its value as a routine alternative technique.
Answers are grounded in this paper and cite their sources.
TALV implantation shows worrisome ischemic stroke rates in failed transvenous CRT; leaves open optimal antithrombotic strategies for endocardial LV leads.
PURPOSE: Cardiac resynchronization therapy (CRT) is an established therapeutic option in selected heart failure patients (pts). However, the transvenous left ventricular (LV) lead implantation remains ineffectual in a considerable number of pts. Transapical LV (TALV) lead implantation is an alternative minimally invasive, surgical, endocardial implantation technique. The aim of the present prospective study is to determine the long-term outcome, including the cerebral thromboembolic complications, of pts who underwent TALV lead placement. METHODS: Twenty-six CRT candidates (19 men (78 %); mean age 61 ± 10 years) with a previously failed transvenous approach underwent TALV lead placement as a last resort therapy. The following data was collected: mortality rate, reoperation rate, and cerebrovascular event rate. Patients underwent a cerebral CT scan to determine any possible cerebrovascular event related to the presence of the TALV lead. RESULTS: Eleven out of 26 (47 %) patients survived after a median follow-up of 40 ± 24.5 months. Major acute ischemic stroke occurred in two cases, while in one case transient ischemic stroke was observed. Cerebral CT scan examination performed in asymptomatic patients revealed chronic ischemic lesions with minimal extension in two patients. Reoperation occurred in one case due to TALV lead fracture. CONCLUSIONS: This is the first study reporting the long-term outcome, mortality, and thromboembolic event rate exclusively after TALV lead implantation. Patients who underwent TALV lead implantation have a comparable long-term mortality rate to conventional CRT, although a major ischemic cerebrovascular event after TALV lead implantation is worrisome and has an impact on the outcome.
No takes yet. Share an insight, caveat, or question.
Kis et al. (2016) conducted an observational in Heart Failure (n=26). Transapical left ventricular (TALV) lead implantation was evaluated on Survival rate. Transapical left ventricular lead implantation resulted in a 47% survival rate over a median 40-month follow-up, but was associated with worrisome major ischemic cerebrovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: